Campbell: souping up its portfolio with Unilever business

Published By Datamonitor

Chevron: looking to leave the Irish market?

Chevron is believed to be in negotiations with the UK's largest independent fuel retailer, Malthurst Fuels, to sell part of its Texaco branded service station network in Ireland. After reporting a loss in 2008, it is possible that Chevron, along with ExxonMobil, the only other oil major left in the country, could follow Shell and Statoil's decision to exit the Irish market altogether.

Published By Datamonitor

DCC/Centrica: LPG sale leaves both sides happy

Irish conglomerate DCC is now the second placed company in the UK LPG market, behind the dominant Calor and ahead of Shell Gas. Building on its acquisition of Alta Gas last year, DCC now has 21% of the market. Meanwhile, Centrica can focus more on direct client relationships - upselling additional services to its huge customer base.

Published By Datamonitor

Elan/AHP: allying to improve sleepy Sonata sales

The agreement gives AHP access to Elan's drug development expertise in an attempt to revive Sonata, which has so far performed disappointingly. Elan should profit from obtaining a share of the drug's existing revenues and increasing its US sales presence. Such mutual benefits will strengthen the existing relationship between Elan and AHP.

Published By Datamonitor

Elan/Biogen Idec: Tysabri sees further safety success

Elan and Biogen Idec can breathe a little easier having announced the second round of positive results about the safety of their multiple sclerosis drug Tysabri. These results, which come less than a year after the voluntary withdrawal of the drug from the US market following the death of two patients from a fatal brain disorder, suggest a promising future could still be possible for Tysabri.

Published By Datamonitor

Elan/Biogen: MS players cower as Antegren looms

Shares of Biogen [BIIB] and Elan [ELN] jumped after they announced they would apply for FDA approval of Antegren for multiple sclerosis treatment ahead of schedule. Antegren is crucial for maintaining Biogen's market share as it is facing stiff competition from Serono's [SRA] Rebif in the US. The drug is equally vital to Elan, which in recent years has suffered numerous financial setbacks.

Published By Datamonitor

Elan: AD vaccine gives new hope

Published By Datamonitor

Elan: Antegren offers renewed hope for growth

Elan [ELN] and Biogen [BIIB] have announced that the Phase III maintenance trial of Antegren in Crohn's disease met the primary end-point of maintenance of response. The new data improves the chance of regulatory approval for Antegren, but the product may still need to find a role in inducing Crohn's disease remission to boost the fortunes of struggling Elan.

Published By Datamonitor

Elan: taking the next step forward

Published By Datamonitor

Elan: to Genomics and Beyond

Published By Datamonitor